Home

Jeffrey Lawrence Schwartz

CIK 1702957 · Chief Executive Officer · last filed 2025-09-08

Jeffrey Lawrence Schwartz is a Chief Executive Officer who has filed 17 SEC Form 4 insider transactions across 7 companies since 2017. The most recent filing, for KMTS, was dated Sep 8, 2025. Across all open-market trades the lifetime net is −$294.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $689.0M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$688.98M

Companies

7

Total Filings

17

Lifetime Open-Market Net

-$294.42M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
KMTS Director 27,030,134 $23.86 $644.94M $0 1 2025-09-08
RPID Director 8,448,860 $2.06 $17.40M $0 4 2024-05-28
SpringWorks Therapeutics, Inc. (SWTX) Delisted Director 3,091,879 $46.99 $145.29M -$320.07M 8 2023-05-25
BCLS Acquisition Corp. (BLSA) Delisted Chief Executive Officer 487,500 $10.04 $4.89M $0 1 2020-10-26
ANNX 10%+ Owner 2,841,628 $4.97 $14.12M $40.80M 1 2020-07-28
REPL 10%+ Owner 2,338,968 $5.35 $12.51M $45.00M 1 2018-07-26
MARINUS PHARMACEUTICALS, INC. (MRNS) Delisted 10%+ Owner 994,363 $0.55 $546.9K -$60.15M 1 2017-12-19

Recent Filings

17 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2025-09-08 KMTS Grant (A) +10,909 $0 EDGAR
2024-05-28 RPID Grant (A) +14,300 $0 EDGAR
2023-05-25 SpringWorks Therapeutics, Inc. (SWTX) Delisted Grant (A) +4,648 $0 EDGAR
2023-05-05 RPID Grant (A) — $0 EDGAR
2023-03-20 SpringWorks Therapeutics, Inc. (SWTX) Delisted Sell (S) −1,750,000 -$49.88M EDGAR
2022-06-10 RPID Grant (A) — $0 EDGAR
2022-05-20 SpringWorks Therapeutics, Inc. (SWTX) Delisted Grant (A) +4,818 $0 EDGAR
2021-08-12 SpringWorks Therapeutics, Inc. (SWTX) Delisted Sell (S) −4,000,000 -$281.00M EDGAR
2021-07-16 RPID Grant (A) — $0 EDGAR
2021-05-24 SpringWorks Therapeutics, Inc. (SWTX) Delisted Grant (A) +1,106 $0 EDGAR
Showing 1–10 of 17
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.